Pierre Blanchard, Radiation Oncology Clinical section chief at Gustave Roussy Cancer Institute, shared on X:
“Excellent discussion by Silke Gillessen, Bertrand Tombal, on intermittent ADT/ARPI in hormone naïve metastatic prostrate cancer at GETUG research days.
New trials needed, especially for patients with deep PSA response (<0,2 ng/ml) after dual ADT/ARPI.”
Source: Pierre Blanchard/X
